• 1. Embedding cyclic nitrone in mesoporous silica particles for EPR spin trapping of superoxide and other radicals?
  Eric Besson,Stéphane Gastaldi,Emily Bloch,Selma Aslan,Hakim Karoui,Olivier Ouari,Micael Hardy Analyst, 2019,144, 4194-4203
• 2. Emergence of cationic polyamine dendrimersomes: design, stimuli sensitivity and potential biomedical applications
  Partha Laskar,Christine Dufès Nanoscale Adv., 2021,3, 6007-6026
• 3. Excellent peroxidase mimicking property of CuO/Pt nanocomposites and their application as an ascorbic acid sensor?
  Xinhuan Wang,Shuangfei Cai,Cui Qi Analyst, 2017,142, 2500-2506
• 4. Emerging 2D hybrid nanomaterials: towards enhanced sensitive and selective conductometric gas sensors at room temperature
  Hanie Hashtroudi,Ian D. R. Mackinnon J. Mater. Chem. C, 2020,8, 13108-13126
• 5. Evolved polymerases facilitate selection of fully 2′-OMe-modified aptamers?
  Zhixia Liu,Tingjian Chen,Floyd E. Romesberg Chem. Sci., 2017,8, 8179-8182

Professional Introduction to Compound with CAS No. 72597-18-3 and Product Name: Cbz-D-prolinol

The compound with CAS No. 72597-18-3 and the product name Cbz-D-prolinol represents a significant advancement in the field of peptidomimetics and protease inhibition. This compound, chemically known as N-carbobenzyloxy-D-prolinol, has garnered considerable attention due to its unique structural properties and its potential applications in pharmaceutical research. The Cbz-D-prolinol moiety is particularly noteworthy as it incorporates a protected form of D-proline, which is a crucial building block in the synthesis of peptide analogs and has been extensively studied for its role in modulating enzyme activity.

Recent research has highlighted the importance of Cbz-D-prolinol in the development of novel therapeutic agents. D-Proline, due to its non-proline nature, exhibits distinct conformational preferences that can influence the binding affinity and specificity of peptide-based drugs. The carbobenzyloxy (Cbz) group serves as an effective protecting group for the amino group of proline, ensuring stability during synthetic processes while maintaining the integrity of the peptide backbone. This combination makes Cbz-D-prolinol an invaluable intermediate in the synthesis of complex peptidomimetics designed to target specific biological pathways.

In the realm of protease inhibition, Cbz-D-prolinol has been explored as a key component in the development of inhibitors for various proteases, including those implicated in cancer, inflammation, and infectious diseases. The chirality provided by the D-isomer of proline allows for selective binding to specific protease active sites, thereby enhancing the efficacy of inhibitory agents. For instance, studies have demonstrated that peptidomimetics incorporating Cbz-D-prolinol exhibit high potency against serine proteases such as chymotrypsin and elastase. These findings are particularly relevant in light of recent advancements in targeted therapy, where precise modulation of enzyme activity is critical for therapeutic success.

The structural versatility of Cbz-D-prolinol also makes it a valuable tool in drug discovery efforts aimed at addressing unmet medical needs. By serving as a scaffold for further derivatization, this compound enables researchers to explore diverse chemical libraries and identify novel pharmacophores. The use of Cbz-D-prolinol in combinatorial chemistry and high-throughput screening (HTS) protocols has led to the identification of several lead compounds with promising biological activity. These discoveries underscore the importance of Cbz-D-prolinol as a foundational building block in modern medicinal chemistry.

Moreover, the synthesis of Cbz-D-prolinol exemplifies the growing sophistication of peptide chemistry techniques. Modern synthetic methodologies have enabled the efficient preparation of complex peptidomimetics like Cbz-D-prolinol, often through multi-step processes that require precise control over reaction conditions. Advances in solid-phase synthesis and enzymatic catalysis have further streamlined these processes, making it feasible to produce large quantities of high-purity material for preclinical and clinical studies. Such improvements are essential for translating laboratory discoveries into viable therapeutics.

The pharmacokinetic properties of compounds derived from Cbz-D-prolinol have also been extensively studied. The stability provided by the Cbz group ensures that these peptidomimetics remain intact during metabolic processes, thereby improving their bioavailability. Additionally, the D-isomer configuration can influence drug distribution and excretion rates, offering opportunities to optimize therapeutic profiles. These considerations are critical in drug development, where achieving optimal pharmacokinetic parameters is often as important as demonstrating biological activity.

Recent clinical trials have begun to explore the potential therapeutic applications of peptidomimetics incorporating Cbz-D-prolinol. Preliminary results suggest that these compounds exhibit significant promise in treating conditions such as cancer and neurodegenerative diseases. For example, studies have shown that certain peptidomimetics derived from Cbz-D-prolinol can inhibit tumor growth by targeting specific signaling pathways involved in cancer progression. Similarly, research into neuroprotective agents has identified derivatives that may slow down disease progression in conditions like Alzheimer's disease by modulating proteolytic enzymes associated with neuroinflammation.

The future direction of research involving Cbz-D-prolinol is likely to focus on expanding its applications into new therapeutic areas. Innovations in computational chemistry and machine learning are expected to accelerate the discovery process by enabling virtual screening and de novo design of peptidomimetics with enhanced properties. Additionally, advances in biocatalysis may provide more sustainable synthetic routes for producing Cbz-D-prolinol, aligning with global efforts toward green chemistry principles.

In conclusion, CAS No. 72597-18-3 and its corresponding product name Cbz-D-prolinol represent a cornerstone in modern peptidomimetic chemistry. Their unique structural features and versatile applications make them indispensable tools for drug discovery and development. As research continues to uncover new therapeutic possibilities, compounds like Cbz-D-prolinol will undoubtedly play a pivotal role in addressing some of medicine's most pressing challenges.

• 1142-20-7(N-[(Benzyloxy)carbonyl]-L-alanine)
• 1155-64-2(H-Lys(Z)-OH)
• 6216-63-3(Z-Pro-OL)
• 1138-80-3(Z-Glycine)
• 1148-11-4(Carbobenzoxyproline)
• 105706-75-0(1-Cbz-2-Hydroxymethylpiperidine)
• 1145-80-8(N-Carboxybenzyl-L-serine)
• 1152-61-0(Z-Asp-OH)
• 1155-62-0(N-Carbobenzoxy-L-glutamic acid)
• 1149-26-4(N-Cbz-L-valine)